Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Agilent Technologies (NY: A )

114.99 USD -4.31 (-3.61%)
Official Closing Price Updated: 7:29 PM EST, Mar 4, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,725,019
Open 118.69
Bid (Size) 113.00 (1)
Ask (Size) 116.60 (1)
Prev. Close 119.30
Today's Range 113.34 - 118.83
52wk Range 61.13 - 136.98
Shares Outstanding 319,952,126
Dividend Yield 0.67%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Agilent Technologies Announces Proposed Offering of Senior Notes
Agilent Technologies announces proposed offering of senior notes. 
From Business Wire News Releases
Agilent to Acquire Resolution Bioscience, Strengthening Leadership Position in Cancer Diagnostics
Agilent to acquire Resolution Bioscience, strengthening leadership position in cancer diagnostics. 
From Business Wire News Releases

Performance

YTD
-3.08%
-3.08%
1 Month
-6.66%
-6.66%
3 Month
+1.24%
+1.24%
6 Month
+15.41%
+15.41%
1 Year
+36.32%
+36.32%

More News

Read More
Agilent Announces Darlene Solomon Award Presented to University of Geneva Scientist Noemi Jiménez-Rojo
From Business Wire News Releases
Agilent PD-L1 IHC 22C3 pharmDx Receives Expanded FDA Approval in Non-small Cell Lung Cancer (NSCLC)
From Business Wire News Releases
Agilent Ranks No. 2 on Barron’s List of America’s Most Sustainable Companies
From Business Wire News Releases
Agilent Technologies Announces Pricing of $850 Million of Senior Notes
From Business Wire News Releases
Agilent Announces Immunoassay Kit to Detect SARS-CoV-2 Antibodies
From Business Wire News Releases
Agilent Announces Higher-Sensitivity XF Analysis Solution for Low Abundant Immune Cell Metabolic Analysis
From Business Wire News Releases
Agilent Reports First-Quarter Fiscal Year 2021 Financial Results
From Business Wire News Releases
FDA Approves Regeneron/Sanofi's Libtayo For Front-Line Lung Cancer
Tags News Non/Small Cell Lung Cancer General
From Benzinga
Noteworthy Wednesday Option Activity: A, NOW, GRMN
Tags Stocks
From Market News Video
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.